Abstract:
Glioblastoma Multiforme is most lethal tumor of brain. The current standard treatment remains palliative with overall median survival of 12 to 15 months, owing to recurrence of disease and therapeutic resistance. Recent Transcriptome analysis has identified upregulation of carbonic anhydrase II as a treatment resistance factor in glioblastoma. WNT signaling holds crucial role in GBM pathogenesis, angiogenesis, invasion and resistance to therapy. The hallmark of the Wntß-catenin pathway is the accumulation and translocation ofß-catenin. B-catenin binds with BCL3 and overexpression of BCL3 provides resistance to TMZ via CAII. Therefore, we planned to investigate the antiglioblastoma potential of Dorozolamide against GBM and Wnt pathway.The Growth Inhibitory effect of Dorozolamide and TMZ against glioblastoma (U87 cells) was investigated using MTT assay while the effect on migration was assessed using wound healing assay and modulation of Wnt signaling pathway was assessed using qRT PCR. Dorozolamide and TMZ significantly inhibited the growth and migration of U87 cells. Expression ofß-catenin, ASCL1, PLAGL2, TWIST, BCL3 and CA II protein were also downregulated after treatment of Dorozolamide. CA II inhibitor Dorozolamide has a potential to inhibit glioblastoma cells via targeting CA II and Wnt signaling pathway.
Page(s):
DOI:
DOI not available
Published:
Journal: Abstract Book on 9th Annual Neuroscience Conference (ANC-23) August 12-13, 2023 , Volume: 0, Issue: 0, Year: 2023